L-tyrosine liposomal
Selected indexed studies
- Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models. (J Mol Neurosci, 2021) [PMID:34125397]
- Genetically Engineered Macrophages Co-Loaded with CD47 Inhibitors Synergistically Reconstruct Efferocytosis and Improve Cardiac Remodeling Post Myocardial Ischemia Reperfusion Injury. (Adv Healthc Mater, 2024) [PMID:38198534]
- Chimeric nanobody-decorated liposomes by self-assembly. (Nat Nanotechnol, 2024) [PMID:38374413]
_Worker-drafted node — pending editorial review._
Connections
L-tyrosine liposomal helps
L-tyrosine liposomal protects against
Sources
- Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models. (2021) pubmed
- Genetically Engineered Macrophages Co-Loaded with CD47 Inhibitors Synergistically Reconstruct Efferocytosis and Improve Cardiac Remodeling Post Myocardial Ischemia Reperfusion Injury. (2024) pubmed
- Chimeric nanobody-decorated liposomes by self-assembly. (2024) pubmed
- Mechanistic studies of peroxynitrite-mediated tyrosine nitration in membranes using the hydrophobic probe N-t-BOC-L-tyrosine tert-butyl ester. (2006) pubmed
- Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice. (2015) pubmed
- Tyrosinase-Loaded Multicompartment Microreactor toward Melanoma Depletion. (2019) pubmed
- 3D printing injectable microbeads using a composite liposomal ink for local treatment of peritoneal diseases. (2024) pubmed
- Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations. (2004) pubmed
- Antiradical Activity of Dopamine, L-DOPA, Adrenaline, and Noradrenaline in Water/Methanol and in Liposomal Systems. (2022) pubmed
- Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study. (2025) pubmed